Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.S. Food and Drug Administration does not plan to convene an advisory committee for its review of the MOLBREEVI biologics license …
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee Read More